A micro-cap “fallen angel” in HMLV PCBs: if Icape proves governance and lifts margins through integration, the valuation discount could unwind dramatically.
Overview
As of early 2026, Icape Holding (ALICA.PA) is positioned as a global specialist in the supply chain for printed circuit boards and custom electromechanical “technical parts,” serving the High-Mix, Low-Volume segment with 3,000+ active customers across ~70 countries. After its July 2022 IPO, the company encountered a “fallen angel” period in 2023–2024: an industry-wide post-pandemic destocking cycle, stagnation in key European markets (notably Germany), and a reputationally damaging accounting fraud in its US subsidiary. Recent disclosures show a tangible turnaround: H1’25 revenue rose +13.1% to €102.0m, supported by both organic recovery and active M&A integration (UK, Japan, Italy). The business is split into the core ICAPE PCB activity (~80% of revenue) and CIPEM technical parts (~20%), with cross-selling designed to deepen customer entrenchment and raise share-of-wallet. Icape differentiates itself from commoditized distributors by offering engineering (DFM), on-the-ground quality audits in Asia, testing labs, and complex logistics—services that matter because PCB failure risk in medical/industrial/EV applications far outweighs component cost. Strategically, management is advancing a “China+1” and “Global & Local” roadmap; NTW (Japan) is a pivotal acquisition that opens the Japanese OEM market and expands Southeast Asian sourcing, partially hedging China geopolitical concentration. Despite improving fundamentals, Icape trades at a steep discount (~5.7x EV/EBITDA vs ~24x for NCAB), reflecting lower current margins (~7%), micro-cap illiquidity, and a lingering governance discount. The core opportunity is a re-rating if integration and margin expansion toward the ~9.5% target become consistent and credible.